Dr. McKearn brings 25 years of scientific and operational expertise in pharmaceutical research and development at Kalypsys, Inc., Pharmacia, G.D. Searle & Co., and E.I. DuPont de Nemours and Company.
"We've known John since Pfizer bought Pharmacia back in 2003 and have kept in close contact ever since," said Mr. Schmelter. "John's strong scientific training and operational expertise will further our capabilities in sourcing and adding value to our biopharmaceutical portfolio."
While leading Kalypsys, Inc., a privately held biotechnology company in San Diego, Dr. McKearn raised more than $150 million in private equity from 2003-2006. As head of Research for Searle and Pharmacia, Dr. McKearn was an important contributor to the discovery, development and launch of no fewer than eight new prescription drugs, including Celebrex, one of the leading pharmaceuticals to treat arthritis.
"I believe in the quality of RiverVest's personnel, investors and portfolio, along with their vast industry and academic networks," said Dr. McKearn. "Fund I has had an impressive track record, and I look forward to applying my expertise to building RiverVest's biopharmaceutical presence."
Dr. McKearn holds a Ph.D. in immunology from the University of Chicago and a B.S. in biology from Northern Illinois University. He currently serves as a member of the board of directors for IDM Pharma (formerly Epimmune) and for Keel Pharmaceuticals.
About RiverVest Venture Partners
RiverVest Venture Partners is a venture capital firm investing in
promising life sciences companies nationwide. RiverVest applies both its
capital and its team's diverse range of expertise to create and grow
successful enterprises that address unmet medical needs in major markets.
RiverVest's extensive national network and privileged access to
|SOURCE RiverVest Venture Partners|
Copyright©2008 PR Newswire.
All rights reserved